Could a simple scan replace biopsies for breast cancer?
NCT ID NCT05923268
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new radioactive imaging agent that binds to the HER2 protein, which is important for guiding breast cancer treatment. Ten women with known HER2-positive or HER2-negative breast cancer received one injection of the agent, followed by several SPECT scans over 24 hours. The goal was to see if the scan could accurately show HER2 levels in tumors, potentially offering a non-invasive way to determine HER2 status.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Technetium-99m-labelled designed ankyrin repeat protein ([99mTc]Tc-G3-(G3S)3C)
What this could lead to
If successful, this could offer a non-invasive way to determine HER2 status in breast cancer, potentially reducing the need for biopsies.
What could go wrong
This is a very small, early imaging study with only 10 participants. It is not designed to prove treatment benefit, and the agent may not accurately distinguish HER2-positive from HER2-negative tumors in larger, more diverse groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Olga
Tomsk, Russia